Manufactured Object

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

1 day ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

2 days ago talkbio0Tagged Antisense Oligonucleotides, Aortic Valve Insufficiency, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments

2 days ago talkbio0Tagged AAVrh74, CHARGE Syndrome, drug safety, ELEVIDYS, gene therapy, Muscular Dystrophy, Duchenne, patient deaths, Regulatory Action, Ships, Suspensions, United States Food and Drug Administration

Sarepta; Elevidys; FDA; HHS; gene therapy; Duchenne muscular dystrophy; drug safety; shipping suspension; patient deaths; AAVrh74; regulatory action

Endpoints 11: The Most Promising Biotech Companies to Watch in 2025 Revealed Live in Boston

6 days ago talkbio0Tagged biotech industry, City of Boston, Endpoints

Endpoints 11; biotech companies; Boston; biotech awards; biotech industry

Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek

1 week ago talkbio0Tagged ALYFTREK, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation, Health care facility, NHS England, Nitroglycerin/Sodium Citrate/Ethanol Solution, Reimbursement, triple therapy, UK

Vertex; NHS England; Alyftrek; cystic fibrosis; reimbursement agreement; triple therapy; CFTR gene mutation; NICE; UK healthcare

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

2 weeks ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

1 month ago talkbio0Tagged BioNTech, BNT211, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Clinical Trials, Gaithersburg, layoffs, Manufacturing Facilities, Maryland (geographic location)

BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial

Lark Health Launches LarkVantage: AI-Powered Platform to Manage GLP-1 Costs

1 month ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, authorization, cost management, Gibbs, Glucagon-Like Peptide 1, Health care facility, Health Planning, Lark Health, LarkVantage, Pharmacy Benefit Manager, utilization qualifier, Weight maintenance regimen

Lark Health; LarkVantage; GLP-1 cost management; AI healthcare; prior authorization; utilization management; PBM; health plans; weight management; Matthew Gibbs